Sangamo BioSciences Inc

Most Recent

  • uploads///dna _
    Earnings Report

    Sangamo Therapeutics Rose despite Q2 Sales Miss, Higher Losses

    Sangamo Therapeutics (SGMO) stock rose ~16% in afternoon trading. SGMO released its Q2 earnings results on August 8 after the market closed.

    By Sarah Collins
  • uploads///biology _
    Company & Industry Overviews

    Why Sangamo Therapeutics Stock Is Down More than 22% Today

    Today, Sangamo Therapeutics (SGMO) stock is down over 22% in afternoon trading. Yesterday, SGMO stock closed at $19.05.

    By Sarah Collins
  • uploads///SGMO net loss
    Company & Industry Overviews

    How Are Sangamo Therapeutics’ Earnings and Expenses Trending?

    In the first nine months of 2018, Sangamo Therapeutics (SGMO) reported net income of -$49.7 million compared to -$41.5 million in the same period the prior year.

    By Daniel Collins
  • uploads///Sangamo
    Company & Industry Overviews

    A Financial Overview of Sangamo Therapeutics in December 2018

    In the first nine months of 2018, Sangamo Therapeutics’ (SGMO) net revenues grew ~145% to reach $57.6 million from $23.5 million.

    By Daniel Collins
  • uploads///molecule _
    Company & Industry Overviews

    Taking Stock of Sangamo’s Financial Performance

    In this series, we explore Sangamo’s financials, analysts’ views on the stock, and the company’s valuation metrics.

    By Kenneth Smith
  • uploads///flasks _
    Company & Industry Overviews

    CRISPR Therapeutics: Analysts’ View in November

    On November 9, CRISPR Therapeutics’ (CRSP) stock price closed at $36.37, which is an ~3.53% decline from its close of $37.70 on November 8.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Audentes Therapeutics’ Promising Product Pipeline

    In this series, we’ll take a look at six stocks with a focus on gene therapy that have promising products in their pipelines.

    By Kenneth Smith
  • uploads///CRSP
    Company & Industry Overviews

    How CRISPR Therapeutics Is Positioned in September

    CRISPR Therapeutics (CRSP) reported net collaboration revenues of $1.1 million in the second quarter of 2018 compared to $3.6 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///hospital _
    Company & Industry Overviews

    Bluebird Bio’s Valuation on September 6

    Bluebird Bio (BLUE) reported a net loss of $2.91 per share on revenues of $7.8 million in Q2 2018, a 53% decline year-over-year.

    By Mike Benson
  • uploads///cells _
    Company & Industry Overviews

    CRISPR Stock Has Seen Soild Growth in the Last 12 Months

    CRISPR Therapeutics has risen 24% between May 11 and May 17.

    By Daniel Collins
  • uploads///Bioverativ
    Company & Industry Overviews

    Analysts’ Recommendations for Bioverativ in January 2018

    Fourteen analysts were tracking Bioverativ in January 2018. Four analysts recommended “strong buys,” while two recommended “buys” on the stock.

    By Daniel Collins
  • uploads///hemophilia
    Company & Industry Overviews

    The Evolution of Hemophilia Treatment—And What It Means for BioMarin

    BioMarin’s BMN 270 is a gene therapy being investigated for hemophilia A. On April 20, it announced early data of the phase-1 and phase-2 study of BMN 270.

    By Jillian Dabney
  • uploads///hemophilia
    Company & Industry Overviews

    Could Gene Therapy Be a Next-Generation Treatment for Hemophilia?

    Gene therapy is the emerging platform for hemophilia care. If approved, it would be a paradigm.

    By Jillian Dabney
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.